In a 47‑year‑old man with decompensated alcoholic cirrhosis, hypoalbuminemia, elevated INR, thrombocytopenia, macrocytosis, and persistent ascites (as reflected by the provided laboratory data), what diagnostic tests and medication regimen should be initiated?

Management of Decompensated Cirrhosis with Ascites and Acute Kidney Injury

This patient requires immediate diagnostic paracentesis to rule out spontaneous bacterial peritonitis (SBP), initiation of combination diuretic therapy (spironolactone 100 mg + furosemide 40 mg daily), sodium restriction to <5 g/day, and urgent evaluation for liver transplantation given the progressive decompensation with acute kidney injury. 1

Critical Diagnostic Tests Required

Immediate Paracentesis (Priority #1)

Perform diagnostic paracentesis immediately on hospital admission to rule out SBP, as this patient has decompensated cirrhosis with ascites and worsening clinical parameters (rising creatinine from 0.64 to 2.14, declining sodium from 137 to 126, rising bilirubin from 3.3 to 4.8). 1 The ascitic fluid analysis from the most recent paracentesis shows 87 total nucleated cells with only 6% neutrophils, which is reassuring for absence of SBP (cutoff is >250 neutrophils/mm³).

Required ascitic fluid studies:

• Cell count with differential (manual or automated flow cytometry) 1
• Bedside inoculation into blood culture bottles 1
• Serum-ascites albumin gradient (SAAG): The peritoneal fluid albumin of 0.3 with serum albumin 2.4 gives SAAG of 2.1, confirming portal hypertension as the cause 1
• Total protein concentration (already done: 0.9 g/dL, indicating high risk for SBP) 1

Monitoring for Hepatorenal Syndrome

The progressive rise in creatinine (0.64→1.34→1.66→2.13→2.14) with declining sodium (137→134→129→126) and low BUN (3-4 initially, now 36-38) suggests evolving hepatorenal syndrome-acute kidney injury (HRS-AKI). Discontinue all diuretics immediately given the Stage 2 AKI (creatinine >2x baseline). 2, 3

Additional Required Tests

• Repeat diagnostic paracentesis if any signs of infection develop (fever, abdominal pain, worsening encephalopathy, rising WBC, or worsening renal function) 1
• Urine sodium concentration: A spot urine Na/K ratio >1 suggests adequate natriuresis (>78 mmol/day) 4
• Screen for precipitating factors: The elevated ethanol level (138 mg/dL) and positive PEth confirms ongoing alcohol use, which must be addressed 5

Medication Regimen

Diuretic Management (Currently Contraindicated)

Stop all diuretics immediately due to Stage 2 AKI (creatinine 2.14, up from baseline ~0.65) and severe hyponatremia (sodium 126). 1 The guidelines are explicit:

• Serum sodium 121-125 mmol/L with elevated creatinine (>150 μmol/L or rising): Stop diuretics and give volume expansion 6
• This patient has sodium 126 with creatinine 2.14 mg/dL (189 μmol/L), meeting criteria for diuretic cessation

Volume Expansion for HRS-AKI

Administer 20% albumin at 1 g/kg body weight (maximum 100 g) for two consecutive days for presumed HRS-AKI without obvious precipitating cause. 2 This patient has:

• Rising creatinine without clear prerenal cause (BUN initially very low at 3-4)
• No evidence of ATN (urine studies not shown, but clinical picture consistent with HRS)
• Declining GFR (119→66→51→38→37)

Consider terlipressin plus albumin if HRS-AKI persists after initial albumin therapy. Terlipressin improves reversal of HRS-AKI (39% vs 18% with placebo) and should be started promptly in hospitalized patients with Stage 2 HRS-AKI without ACLF-3. 3, 7 Norepinephrine is an alternative if shock develops. 3

SBP Prophylaxis

Primary prophylaxis is indicated given ascitic protein <1.5 g/dL (0.9 g/dL in this patient). 1 Options include:

• Norfloxacin 400 mg once daily, OR
• Ciprofloxacin 500 mg once daily, OR
• Co-trimoxazole (800/160 mg) once daily

However, defer initiation until AKI resolves to avoid nephrotoxicity from quinolones. 2

Sodium Restriction

Restrict dietary sodium to <5-6.5 g/day (87-113 mmol sodium) with no-added-salt diet and avoidance of precooked meals. 1 This is a cornerstone of ascites management.

Fluid Restriction

Restrict fluids to 1-1.5 L/day given severe hyponatremia (sodium 126) with clinical hypervolemia (ascites, anasarca). 1 Fluid restriction is specifically indicated when sodium <125 mmol/L. 4

Avoid Nephrotoxic Agents

Discontinue immediately:

• NSAIDs (cause sodium retention, hyponatremia, AKI) 2
• ACE inhibitors/ARBs (cause hypotension, renal impairment) 2
• Aminoglycosides (nephrotoxic) 2
• Beta-blockers should be held during AKI 2

Nutritional Support

Provide adequate nutrition with attention to protein intake (not restricted unless severe encephalopathy develops). Thiamine supplementation given alcohol use disorder. 5

Management of Hyponatremia

The progressive hyponatremia (137→134→129→126) with rising creatinine represents hypovolemic hyponatremia during diuretic therapy (if diuretics were being given) or dilutional hyponatremia from HRS-AKI. 1, 8

Management approach:

1. Discontinue diuretics (already recommended above) 1
2. Fluid restriction to 1-1.5 L/day 1
3. Avoid rapid correction: Do not increase sodium by >12 mmol/L per 24 hours to prevent osmotic demyelination 6
4. Consider vasoconstrictor therapy (terlipressin or norepinephrine) which may improve sodium levels 8
5. Hypertonic saline (3%) only if severely symptomatic with acute hyponatremia 1
6. Vaptans (tolvaptan) may be considered in recurrent/refractory hyponatremia, though use in cirrhosis requires caution 4, 8

When to Resume Diuretics

Once AKI resolves (creatinine returns toward baseline ~0.65-0.70) and sodium improves (>130 mmol/L), restart diuretics with:

• Combination therapy: Spironolactone 100 mg + furosemide 40 mg once daily (preferred for hospitalized patients with recurrent severe ascites) 1
• Monitor weight daily (goal: 0.5 kg/day loss without peripheral edema, 1 kg/day with edema) 9
• Check electrolytes every 2-3 days initially 4
• Titrate upward every 3-5 days if inadequate response (max: spironolactone 400 mg, furosemide 160 mg) 1

Liver Transplantation Evaluation

Refer urgently for liver transplantation evaluation. 6, 1 This patient has multiple indications:

• Development of ascites (median survival 1.1 years) 7
• Hepatorenal syndrome (median survival <2 weeks untreated) 7
• Progressive decompensation despite therapy
• MELD-Na score likely >15 given labs (bilirubin 3.2-4.8, INR 1.7-2.0, creatinine 2.14, sodium 126)

Alcohol Cessation

Immediate and complete alcohol abstinence is mandatory. 9, 5 The positive ethanol level (138 mg/dL) and elevated PEth (62/46) confirm recent heavy use. Alcohol cessation is the most effective strategy to prevent disease progression and is essential for transplant candidacy. 5

Manage alcohol withdrawal syndrome in the inpatient setting with benzodiazepines per CIWA protocol. 5

Common Pitfalls to Avoid

1. Do not continue diuretics during AKI: This worsens renal function and delays HRS-AKI diagnosis 2
2. Do not restrict protein: Unless severe encephalopathy develops, protein restriction worsens malnutrition 5
3. Do not use NSAIDs: Even COX-2 inhibitors are not proven safe in ascites 2
4. Do not rapidly correct hyponatremia: Risk of osmotic demyelination syndrome 6
5. Do not delay paracentesis: SBP can be asymptomatic and fatal if untreated 6, 1
6. Do not forget transplant evaluation: Development of ascites is an indication for listing 6, 1

Monitoring Plan

Daily while hospitalized:

• Weight, vital signs, mental status
• Intake/output
• Abdominal girth if tense ascites

Every 2-3 days:

• Comprehensive metabolic panel (sodium, potassium, creatinine, BUN)
• CBC (watch for infection)

Weekly:

• Liver function tests (albumin, bilirubin, INR)
• Reassess volume status and need for therapeutic paracentesis